Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines.

Laboratory medicine Pub Date : 2024-03-07 DOI:10.1093/labmed/lmad044

Lara Milevoj Kopcinovic, Adriana Unic, Nora Nikolac Gabaj, Marijana Miler, Alen Vrtaric, Marija Bozovic, Mario Stefanovic

{"title":"Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines.","authors":"Lara Milevoj Kopcinovic, Adriana Unic, Nora Nikolac Gabaj, Marijana Miler, Alen Vrtaric, Marija Bozovic, Mario Stefanovic","doi":"10.1093/labmed/lmad044","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the association of immune response with vaccination adverse effects at peak anti-receptor-binding domain spike subunit 1 (anti-RBDS1) IgG after full vaccination with Comirnaty, Spikevax, or Vaxzevria.Methods: Anti-RBDS1 IgG concentrations after vaccination were determined in healthy adults vaccinated with the Comirnaty, Spikevax, and Vaxzevria vaccines. The association of reactogenicity and peak antibody response after vaccination was tested.Results: Anti-RBDS1 IgG values were significantly higher in the Comirnaty and Spikevax group, compared with the Vaxzevria group (P < .001). Fever and muscle pain were found to be significant independent predictors of peak anti-RBDS1 IgG in the Comirnaty and Spikevax groups (P = .03 and P = .02, respectively). The multivariate model, adjusted for covariates, showed that no association between reactogenicity and peak antibody concentrations was found in the Comirnaty, Spikevax, and Vaxzevria groups.Conclusions: No association between reactogenicity and peak anti-RBDS1 IgG after vaccination with the Comirnaty, Spikevax, and Vaxzevria vaccine was found.","PeriodicalId":17951,"journal":{"name":"Laboratory medicine","volume":" ","pages":"162-168"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/labmed/lmad044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the association of immune response with vaccination adverse effects at peak anti-receptor-binding domain spike subunit 1 (anti-RBDS1) IgG after full vaccination with Comirnaty, Spikevax, or Vaxzevria.

Methods: Anti-RBDS1 IgG concentrations after vaccination were determined in healthy adults vaccinated with the Comirnaty, Spikevax, and Vaxzevria vaccines. The association of reactogenicity and peak antibody response after vaccination was tested.

Results: Anti-RBDS1 IgG values were significantly higher in the Comirnaty and Spikevax group, compared with the Vaxzevria group (P < .001). Fever and muscle pain were found to be significant independent predictors of peak anti-RBDS1 IgG in the Comirnaty and Spikevax groups (P = .03 and P = .02, respectively). The multivariate model, adjusted for covariates, showed that no association between reactogenicity and peak antibody concentrations was found in the Comirnaty, Spikevax, and Vaxzevria groups.

Conclusions: No association between reactogenicity and peak anti-RBDS1 IgG after vaccination with the Comirnaty, Spikevax, and Vaxzevria vaccine was found.

查看原文本刊更多论文

接种不同 SARS-CoV-2 疫苗的未感染过 COVID-19 的个体的反应原性和峰值抗 RBD-S1 IgG 浓度。

目的研究接种Comirnaty、Spikevax或Vaxzevria疫苗后抗受体结合域尖峰亚基1（抗RBDS1）IgG峰值的免疫反应与接种不良反应的关系：测定了接种Comirnaty、Spikevax和Vaxzevria疫苗的健康成人的疫苗接种后抗RBDS1 IgG浓度。测试了疫苗接种后的致反应性与抗体反应峰值之间的关联：结果：与 Vaxzevria 组相比，Comirnaty 和 Spikevax 组的抗 RBDS1 IgG 值明显更高（P < .001）。在 Comirnaty 组和 Spikevax 组，发热和肌肉疼痛是抗 RBDS1 IgG 峰值的重要独立预测因素（P = .03 和 P = .02）。根据协变量调整的多变量模型显示，在Comirnaty组、Spikevax组和Vaxzevria组中，反应原性与抗体峰值浓度之间没有关联：结论：接种Comirnaty、Spikevax和Vaxzevria疫苗后，未发现致反应性与抗RBDS1 IgG峰值之间存在关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Laboratory medicine

自引率

0.00%

发文量